Researchers at Massachusetts Eye and Ear have discovered a group of metabolites that could be used to improve the diagnosis and treatment of AMD.
The Massachusetts Eye and Ear team studied metabolites, or small molecules in the blood of patients with early, intermediate and late-stage AMD, as well as from individuals without AMD.
They found 87 metabolites that were “significantly different” in people with AMD and those without. These molecules also differed between patients with different stages of AMD. This method, dubbed “metabolomics,” could enable the early diagnosis of AMD, allow doctors to personalize treatment for each patient and highlight potential new targets for treatments. The work is published in the journal Ophthalmology, sited below.
For more info: